AI-generated analysis. Always verify with the original filing.
Vistagen Therapeutics reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, including a net loss of $18.9 million, and provided updates on its clinical programs, including the ongoing PALISADE-4 Phase 3 trial for fasedienol and the planned IND submission for refisolone.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On February 12, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial r
Financial Statements and Exhibits. (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated February 12, 2026,
| Metric | Value | Basis |
|---|---|---|
| Sublicense and other revenue | $303.00 | |
| Research and development expense | $14.2K | |
| General and administrative expense | $5.6K | |
| Net loss | $18.9K | |
| Basic and diluted net loss per common share | $-0.45 |
Nick Tressler
Effective: 2025-12